The present invention relates to a pharmaceutical combination comprising:(a) a PPAR agonist；(b) a p38 kinase inhibitor； and optionally(c) one or more pharmaceutically acceptable diluents, excipients or carriers for use in a method of preventing or treating ophthalmic diseases or disorders in a subject.
